Teva Rockets Into A Profit-Taking Zone On Austedo's Big Sales Beat

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its movement disorders drug, Austedo, in the U.S.


Austedo treats involuntary movement disorders like tardive dyskinesia and chorea associated with Huntington's disease. In the September quarter, Austedo brought in $618 million in global sales, including $601 million from the U.S. Analysts projected a respective $560 million and $545 million.

For the year, Teva Pharmaceutical (TEVA) now expects $2.05 billion to $2.15 billion in Austedo sales, up $125 million at the midpoint from the guidance issued three months ago. The Street projected $2.12 billion, which roughly lines up with Teva's new outlook.

In morning trades, Teva stock soared more than 19% to 24.41.

Shares broke out of a cup-with-handle base, topping a buy point at 19.98 on Sept. 30, MarketSurge shows. Though the stock later sank as much as 5.8% below its entry, that wasn't enough to trigger a sell rule. On Wednesday, shares were 21% above their entry.

U.S. Austedo, Generics Bolster Growth

Across all products, Teva earned 78 cents per share, minus some items, on $4.48 billion in sales. Both measures beat forecasts for adjusted profit of 68 cents a share and $4.38 billion. Earnings rose 13% and sales increased 3%. Excluding the impact of exchange rates, sales edged 1% higher.

The company cited strong sales from Austedo and generic products in the U.S., partially offset by lower international generic revenue. It's important to note, Teva also divested its business venture in Japan.

In addition to a strong 38% growth rate from Austedo in the U.S., revenue from migraine prevention drug Ajovy surged 27% to $73 million. Generic products in the U.S. ticketed 7% higher to $1.18 billion. Ajovy sales came up $2 million short, but U.S. generics beat forecasts for $1.07 billion.

Teva reaffirmed its guidance for $630 million to $640 million in full-year sales of Ajovy, and $190 million to $200 million in sales of its antipsychotic Uzedy. But the company lowered the top end of its 2025 total sales outlook by $200 million and now projects $16.8 billion to $17 billion in sales.

The company raised its adjusted earnings guidance to $2.55 to $2.65 a share.

Analysts expected earnings of $2.61 a share and $16.99 billion in sales.

https://www.investors.com/news/technology/teva-stock-teva-pharmaceutical-earnings-q3-2025/